Osimertinib
Osimertinib, sold under the brand name Tagrisso,[4] is a medication used to treat non-small-cell lung carcinomas with specific mutations.[5][6] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
|
| ||||||||||
Osimertinib, sold under the brand name Tagrisso,[4] is a medication used to treat non-small-cell lung carcinomas with specific mutations.[5][6] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.
|
| ||||||||||